HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.

Abstract
Although Parkinson's disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-L-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinson's disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson's disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinson's disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinson's disease.
AuthorsCorey R Hopkins, Craig W Lindsley, Colleen M Niswender
JournalFuture medicinal chemistry (Future Med Chem) Vol. 1 Issue 3 Pg. 501-13 (Jun 2009) ISSN: 1756-8927 [Electronic] England
PMID20161443 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Benzopyrans
  • Glutamates
  • N-phenyl-7-(hydroxyimino)cyclopropa(b)chromen-1a-carboxamide
  • Receptors, Metabotropic Glutamate
  • metabotropic glutamate receptor 4
Topics
  • Allosteric Regulation
  • Benzopyrans (chemistry, therapeutic use)
  • Glutamates (chemistry, therapeutic use)
  • Humans
  • Parkinson Disease (drug therapy)
  • Receptors, Metabotropic Glutamate (chemistry, metabolism, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: